-
Pancreatic cancer is heavy! PD-L1 and CD16 dual-specific NK cell therapy PD-L1 t-haNK showed strong results: 1x increase in total lifetime!
Time of Update: 2021-01-26
From 2017 to 2020, several QUILT clinical trials exploring these combinations of cell therapy, immunomodulating antibodies, adenovirus-based cancer vaccines, and low-dose chemotherapy provide preliminary results that show that in patients with metastatic pancreatic cancer who do not have other FDA-approved treatments, the average survival rate can be more than doubled and can be fully alleviated.
-
Clin Cancer Res: The activity of the trisexual T-cell activation protein HPN536 in malignant tumors that express mesothionin
Time of Update: 2021-01-25
HPN536 can effectively inhibit tumor growth experimental results confirmed that HPN536 can be combined with tumor cells expressing MSLN, and with the surface of T cells CD3, resulting in T cell activity and effective redirect target cell dissolution.
-
To eliminate cancer stem cells, mice with multiple myeloma were treated
Time of Update: 2021-01-25
, ION251 reduces the burden of disease, reduces myeloma stem cell abundance, and improves survival in mice with human myeloma, according to preclinical studies.
-
Clin Cancer Res: Intestinal bacteria predict the response of patients with advanced rectal cancer to new assisted chemotherapy!
Time of Update: 2021-01-25
identified microbial biomarkers associated with nCRT reactions, the researchers constructed a random forest classifier from baseline samples from 37 patients and validated it in another group of 47 patients.
-
What the? A brain tumor is more than just a tumor
Time of Update: 2021-01-25
patients can show headache, nausea, vomiting, epilepsy, blurred vision and other symptoms, but also accompanied by decreased brain function, memory loss, urinary incontinence, speech difficulties.
early abominable symptoms in patients with metastatic tumors, headache, food blur, vomiting, inconvenient mobility, epilepsy, etc.
-
Clin Cancer Res: New Genomic Features of Metastasis Breast Cancer!
Time of Update: 2021-01-25
the mutation characteristics of patients with rMBC and dnMBC were more intensive than the MYB amplification of rMBC (21.1% vs 0%, p=0.0005, q=0.111) when comparing primary tumors by subtype.
-
ASCO GI 2020: Zanidatamab showed long-lasting anti-tumor activity in treated HER2 plus gastroesophageal adenocarcinoma patients
Time of Update: 2021-01-25
patients treated with zandatamab combined with yew alcohol or carpedabin, the objective remission rates were 50 per cent and 57 per cent, respectively, and the disease control rates were 90 per cent and 71 per cent, respectively.
-
ASCO GI 2021: Pabli Pearl Monoantigen significantly improves PFS in MSI-H/dMMR mCRC patients (KEYNOTE-177 study)
Time of Update: 2021-01-25
end points include remission duration (DoR), PFS2 (from random to second-line treatment progression or the time of death for any cause), and health-related quality of life (HRQoL).
results: At the data cut-off, the study included 307 patients, 153 cases in the Paboliju monoantigen and 154 in the chemotherapy group, respectively.
-
Clin Cancer Res: Artificial intelligence against the sky, only based on HE staining tablets can determine the presence of HPV infection!
Time of Update: 2021-01-25
Sebastian and others established deep learning-based HPV-ps based on conventional Sumo-E-Red (HE) staining tablets and evaluated their predictive HPV correlation performance in 273 patients from two different locations (OPSCC; Giessen n=163; Cologne, n=110).
-
JAMA Network Open: Social Media Recruiting Cancer Patients? Perhaps it's too early
Time of Update: 2021-01-25
According to a study published online December 28, 2020 in JAMA Network Open (IF:5.03), researchers on most cancer clinical trial teams largely believe that social media can be a boon to patient recruitment, but at the same time, people don't fully believe in the process.
-
Grigg Ingham teamed up with Cree Gene to develop the next generation of breakthrough gene therapies
Time of Update: 2021-01-25
This new collaboration combines Grigg Ingham's experience in disease mechanism research and gene therapy development with Cree Gene's expertise in virus library building and efficient in vivo AAV screening to provide patients with potentially safer and more efficient new AAV serotypes.
-
ASCO GI 2021: Pabli Juju monoanti-radiation chemotherapy completes the whole process of new auxiliary treatment of local advanced rectal cancer, failed to improve NAR score (NRG-GI002 study)
Time of Update: 2021-01-25
However, the new view on rectal cancer treatment is that total Neoadjuvant Therapy (TNT mode) is safe throughout the procedure, and while the NRG-GI002 study results do not improve the NAR score, TNT may be an acceptable option for patients with very serious conditions, very large tumors, multiple positive lymph nodes, or those who need to retain rectal sphincter.
-
Clin Cancer Res: New hope for dual-specific DLL3 targeted T-cell binding agent AMG 757, small cell lung cancer?
Time of Update: 2021-01-25
AMG757 is a two-specific T-cell binding molecule that targets the half-life extension of DLL3.
the activity of AMG 757 in SCLC cell line, in-place, and patient-sourced Xeno-transplant (PDX) mouse SCLC models.
-
The first is on the market, how is the domestic CAR-T therapy priced?
Time of Update: 2021-01-25
There has been a joke abroad that the biggest side effect of drugs is price, especially for new drugs. days ago, Fosun Kate CAR-T therapy Yikililun race injection application in China has entered the
-
J Hepatol: How do I decide who will receive the next liver transplant?
Time of Update: 2021-01-25
By incorporating HCC-related and non-HCC-related variables (e.g., age, chronic kidney disease), this scoring method allows transplant professionals to prioritize liver cancer patients to be transplanted based on the predicted post-transplant survival rate, which can be used to determine who can receive transplants first.
-
What can we learn from the dramatic decline in cancer deaths in the United States in 2021?
Time of Update: 2021-01-24
According to the latest Global Cancer Burden Data 2020 released by the World Health Organization's International Agency for Research on Cancer (IARC), there will be 19.29 million new cancer cases worl
-
J Clin Oncol: The prognostic results of extended follow-up as a first-line treatment for broad-stage small cell lung cancer (IMpower133 trial)
Time of Update: 2021-01-24
The trial divided untreated ES-SCLC patients into two groups and, on the basis of receiving CP-ET treatment, combined atoju monoantigen (1200 mg IV, day 1) or placebo treatment, a 21-day course of treatment with a total of 4 courses, and then maintained treatment with atropules or placebos until there was an impatient toxicity, disease progression, or loss of clinical benefits.
-
Professor Ma Fei: New progress in breast cancer treatment in 2020
Time of Update: 2021-01-24
neoCARH study, published at the 2020 ASCO Conference, compared for the first time the new auxiliary chemotherapy TCH program with the table-soft star-cyclophosphamide sequential docetaxel-curto-bead monoanti (EC-TH) program, and the results showed that the TCH group The pCR rate was significantly higher in patients than in the EC-TH group (56.1%:38.5%), and the incidence of adverse reactions was similar in terms of safety, indicating that the TCH scheme might be more suitable for new complementary treatments for HER2-positive breast cancer.
-
Clin Cancer Res: Intelligent analysis-based genetic characteristics predict the prognosmation of advanced colorectal cancer using Osali platinum first-line chemotherapy
Time of Update: 2021-01-24
RWE data set FOLFOX first-line treatment patient prognostication in the training queue (n-105), 67 genetic characteristics were cross-verified, indicating that FOLFOXai has the ability to distinguish between mCRC patients with increased or reduced benefit after FOLFOX treatment (IB).
-
CA Cancer J Clin: 2020 U.S. Youth and Young Cancer Statistics Report
Time of Update: 2021-01-24
the incidence of breast cancer has increased by nearly 2% and 0.2% per year in women aged 20-29 and over 30 in the last decade, respectively, while the incidence rate among adolescents has been stable.
